In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $43.00.
Debanjana Chatterjee has given her Buy rating due to a combination of factors including the progress in Pharvaris’s clinical trials and the potential market impact of their products. The completion of enrollment in the Phase 3 RAPIDe-3 study for deucrictibant, aimed at on-demand use in hereditary angioedema (HAE), is a significant milestone with results expected in early 2026. Additionally, the ongoing enrollment in the Phase 3 CHAPTER-3 study for HAE prophylaxis, with results anticipated in the second half of 2026, further supports the company’s growth prospects.
Chatterjee also considers the upcoming launch of sebetralstat, the first oral on-demand HAE drug, as a positive market development. Despite being second-to-market, deucrictibant’s unique mechanism of action and potential higher efficacy may allow it to capture market share, particularly among moderate to severe cases. The company’s strong cash position, with sufficient funds to support operations into the third quarter of 2026, also underpins the Buy rating. These factors combined with updated financial models and expense estimates contribute to the positive outlook for Pharvaris, reflected in the price target adjustment to $43.
According to TipRanks, Chatterjee is an analyst with an average return of -14.2% and a 20.45% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Clearside Biomedical, and Opthea Limited Sponsored ADR.
In another report released on April 11, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.